Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 93 of the 97 references it cites were found in a registry or an index.

Management of multiple myeloma: a systematic review and critical appraisal of published studies

Kumar, Ambuj, Loughran, Thomas, Alsina, Melissa, Durie, Brian GM, Djulbegovic, Benjamin · 2003 · The Lancet Oncology

Abstract

We have done a systematic review of all randomised studies in myeloma, identified through a comprehensive search. Our aim was to investigate and critically examine the effects of various treatment modalities on outcome in patients with multiple myeloma and address 22 specific clinical questions in the management of this disease. As a result of our analysis we identified two therapeutic advances in the management of myeloma that, according to the evidence, are most important for improving outcome. These advances were: introduction of high dose chemotherapy, which appears to be superior to conventional chemotherapy, and the use of bisphosphonates, which decrease the probability of pathological vertebral fractures. However, the overall quality of the body of evidence for myeloma management was poor. Many trials were done with small sample sizes, and did not include reporting power analysis. The majority of studies had inadequate allocation concealment, and few were analysed according to intention to treat principle. We conclude that the quality of total evidence supporting treatment recommendations in myeloma is modest at best and has an ample scope for improvement.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(03)01077-5

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 97 references

Research works printed but not linked: 10

  1. Djulbegovic, 2002, Database for health outcomes and quality of randomized trials in multiple myeloma, Proc Am Soc Clin Oncol, 21, 251a
  2. Lenhard, 1994, Timed-sequential high-dose cyclophosphamide and vincristine in the treatment of multiple myeloma, Cancer, 73, 2113, 10.1002/1097-0142(19940415)73:8<2113::AID-CNCR2820730816>3.0.CO;2-3 · doi:10.1002/1097-0142(19940415)73:8<2113::aid-cncr2820730816>3.0.co;2-3
  3. Musto, 1999, Intensive chemotherapy followed by single or multiple peripheral blood stem cell transplant (PBSCT) improves the prognosis of patients affected by multiple myeloma (MM) with high proliferative activity, Blood, 94, 576a
  4. Morgan, 2002, The MRC Myeloma VII trial of standard versus intensive treatment in patients <65 years of age with multiple myeloma, Blood, 100, 178a
  5. Attal, 2002, Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the “Intergroupe Francophone du Myelome” (IMF 94), Blood, 100, 5a
  6. Cavo, 2002, The “Bologna 96” clinical trial of single vs. double autotransplant for previously untreated multiple myeloma, Blood, 100, 179a
  7. Djulbegovic, 2002, Biophosphonates in multiple myeloma, Cochrane Database Systematic Reviews, 3, CD003188
  8. Heim, 1995, Prospective randomized trial of dichloromethilene bisphosphonate (clodronate) in patients with multiple myeloma, Onkologie, 18, 439
  9. Garton, 1995, Epoetin alfa for the treatment of the anemia of multiple myeloma, Arch Intern Med, 155, 2069, 10.1001/archinte.1995.00430190059008 · doi:10.1001/archinte.1995.00430190059008
  10. Kraj, 2000, The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma, Acta Haematologica Polonica, 31, 379

Cited by

See all 113

Metadata

Authors
Kumar, A., Loughran, T., Alsina, M., Durie, B. G., & Djulbegovic, B.
Affiliations
  • University of South Florida (US)
  • Cedars-Sinai Medical Center (US)
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2003-05
Volume
4
Issue
5
Pages
293-304
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2144719592
Cited by
113
References
97
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 1 · 2016: 3 · 2015: 4 · 2014: 5 · 2013: 5 · 2012: 4
FWCI
1.93
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Surgery › Management of metastatic bone disease
Keywords
multiple myeloma, high-dose chemotherapy, bisphosphonates, pathological vertebral fractures, treatment outcomes, quality of evidence, allocation concealment, intention-to-treat analysis, randomised trials
MeSH terms
Epoetin Alfa, Bortezomib, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Diphosphonates, Drug Administration Schedule, Erythropoietin, Hematinics, Humans, Melphalan, Multiple Myeloma, Neoplasm Staging, Pyrazines, Recombinant Proteins, Time Factors, Transplantation, Autologous, Transplantation, Homologous, Survival Analysis, Bone Marrow Transplantation, Randomized Controlled Trials as Topic, Bone Marrow Purging, Salvage Therapy, Treatment Outcome, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Alkylating, Transplantation Conditioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of multiple myeloma: a systematic review and critical appraisal of published studies. https://app.cochat.ai/papers/10.1016/s1470-2045(03)01077-5
The paper
Kumar, A., Loughran, T., Alsina, M., Durie, B. G., & Djulbegovic, B. (2003). Management of multiple myeloma: a systematic review and critical appraisal of published studies. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(03)01077-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.